

Forigerimod TFA

Cat. No.:	HY-105037A	
Molecular Formula:	C ₁₁₇ H ₁₈₁ N ₃₄ O ₃₂ PS.xC ₂ HF ₃ O ₂	
Sequence Shortening:	RIHMYYSKR-{pSer}-GKPRGYAFIEY (TFA)	
Target:	Autophagy	RIHMYYSKR-{pSer}-GKPRGYAFIEY (TFA salt)
Pathway:	Autophagy	
Storage:	Sealed storage, away from moisture and light, under nitrogen	
	Powder	-80°C 2 years
		-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (Need ultrasonic)
-----------------	--

BIOLOGICAL ACTIVITY

Description Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [1][2][3][4].

In Vivo Forigerimod TFA (P140) (i.v.; 100 µg in 100 µL saline per mouse) directly acts on chaperone-mediated autophagy, rescues MRL/lpr mice from cellular infiltration and autophagy defects occurring in salivary glands^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MRL/lpr mice ^[4]
Dosage:	100 µg in 100 µL saline per mouse
Administration:	Intravenous administration, single
Result:	Corrected the cell content and distribution in MRL/lpr salivary glands. Corrected the defective of autophagy processes in SGs of MRL/lpr mice.

REFERENCES

- [1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
- [2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systemic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.
- [3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA